A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

Background Immunotherapy using a checkpoint inhibitor (CPI) alone or in combination with chemotherapy is the standard of care for treatment‐naive patients with advanced non–small cell lung cancer (NSCLC) without driver mutations for which targeted therapies have been approved. It is unknown whether...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2023-01, Vol.129 (2), p.264-271
Hauptverfasser:	Salous, Tareq, Shukla, Nikhil A., Althouse, Sandra K., Perkins, Susan M., Furqan, Muhammad, Leal, Ticiana, Traynor, Anne M., Feldman, Lawrence E., Hanna, Nasser H., Durm, Greg A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Anemia Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer research Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy docetaxel Female Health services Humans Hypotheses Immune checkpoint inhibitors Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Inhibitors Lung cancer Lung Neoplasms - pathology Male Monoclonal antibodies Mutation Non-small cell lung carcinoma non–small cell lung cancer Null hypothesis Oncology Patients PD-L1 protein Pembrolizumab pemetrexed Programmed Cell Death 1 Receptor - therapeutic use second‐line chemotherapy Small cell lung carcinoma Smoking Solid tumors Squamous cell carcinoma Statistical analysis Survival Targeted cancer therapy Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!